Fig. 3: IFNγ neutralization does not impair CAR.CD19-T cell activation signaling. | Nature Communications

Fig. 3: IFNγ neutralization does not impair CAR.CD19-T cell activation signaling.

From: Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Fig. 3

a Volcano plot of the 14 deregulated genes in CAR.CD19-T cells activated with 0.5 μg/ml Recombinant Human CD19 Fc Chimera Protein for 16 h in the absence or presence of 100 μg/ml emapalumab. The log2FC indicates the mean expression level for each gene. Genes with negative log2FC are downregulated in CAR.CD19-T cells in the presence of emapalumab. b Heatmap displaying the expression of the same genes in untreated NT-T cells, untreated CAR.CD19-T cells and CAR.CD19-T cells treated with 100 μg/ml emapalumab. c STRING tool has been applied to deconvolute the potential interaction network among the 14 genes deregulated in CAR.CD19-T cells in the presence of emapalumab. d Venn diagram that summarizes common genes deregulated both in untreated CAR.CD19 compared to untreated NT-T cells and in CAR.CD19 cultured either in the presence or absence of emapalumab (untreated CAR.CD19-T cells). e Heatmaps displaying the 7 genes specifically upregulated in activated CAR.CD19-T cells, but deregulated in the presence of emapalumab. Data are obtained from three independent experiments, with effector cells generated from 3 HDs. Source data are provided as a Source Data file.

Back to article page